- Home
- ED vs TEVA Comparison
ED vs TEVA Comparison
Compare ED & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ED | TEVA |
|---|---|---|
| Founded | 1884 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5B | 33.5B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | ED | TEVA |
|---|---|---|
| Price | $110.42 | $31.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $107.50 | $38.63 |
| AVG Volume (30 Days) | 1.6M | ★ 4.8M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | ★ 7.63 | N/A |
| EPS | ★ 5.64 | N/A |
| Revenue | ★ $16,918,000,000.00 | N/A |
| Revenue This Year | $9.18 | N/A |
| Revenue Next Year | $4.49 | $3.24 |
| P/E Ratio | ★ $19.59 | $28.19 |
| Revenue Growth | ★ 10.89 | N/A |
| 52 Week Low | $94.96 | $13.04 |
| 52 Week High | $116.23 | $37.35 |
Technical Indicators
Market Signals| Indicator | ED | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 54.69 |
| Support Level | $109.19 | $30.70 |
| Resistance Level | $115.27 | $31.99 |
| Average True Range (ATR) | 1.88 | 0.88 |
| MACD | -0.47 | 0.33 |
| Stochastic Oscillator | 17.50 | 82.96 |
Price Performance
Historical ComparisonAbout ED Consolidated Edison Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.